Patents by Inventor Jin-hua Sun

Jin-hua Sun has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • HEPATITIS C VIRUS INHIBITORS
    Publication number: 20160199355
    Abstract: The present disclosure is generally directed to antiviral compounds, and more specifically directed to combinations of compounds which can inhibit the function of the NS5A protein encoded by Hepatitis C virus (HCV), compositions comprising such combinations, and methods for inhibiting the function of the NS5A protein.
    Type: Application
    Filed: March 11, 2016
    Publication date: July 14, 2016
    Inventors: PIYASENA HEWAWASAM, JOHN F. KADOW, OMAR D. LOPEZ, NICHOLAS A. MEANWELL, YONG TU, ALAN XIANGDONG WANG, NINGNING XU, SAMAYAMUNTHULA VENKATA SATYA ARUN KUMAR GUPTA, POTHUKANURI SRINIVASU, INDASI GOPI KUMAR, PONUGUPATI SURESH KUMAR, MAKONEN BELEMA, ROBERT A. FRIDELL, MIN GAO, JULIE A. LEMM, DONALD R. O'BOYLE, II, JIN-HUA SUN, CHUNFU WANG, YING-KAI WANG
  • Hepatitis C virus inhibitors
    Patent number: 9326973
    Abstract: The present disclosure is generally directed to antiviral compounds, and more specifically directed to combinations of compounds which can inhibit the function of the NS5A protein encoded by Hepatitis C virus (HCV), compositions comprising such combinations, and methods for inhibiting the function of the NS5A protein.
    Type: Grant
    Filed: January 7, 2013
    Date of Patent: May 3, 2016
    Assignee: Bristol-Myers Squibb Company
    Inventors: Piyasena Hewawasam, John F. Kadow, Omar D. Lopez, Nicholas A. Meanwell, Yong Tu, Alan Xiangdong Wang, Ningning Xu, Samayamunthula Venkata Satya Arun Kumar Gupta, Pothukanuri Srinivasu, Indasi Gopi Kumar, Ponugupati Suresh Kumar, Makonen Belema, Robert A. Fridell, Min Gao, Julie A. Lemm, Donald R. O'Boyle, II, Jin-Hua Sun, Chunfu Wang, Ying-Kai Wang
  • METHODS TO IDENTIFY COMBINATIONS OF NS5A TARGETING COMPOUND THAT ACT SYNERGISTICALLY TO INHIBIT HEPATITIS C VIRUS REPLICATION
    Publication number: 20130157894
    Abstract: The present invention is based on the surprising finding that pairs of HCV NS5A-targeting inhibitors can be identified which display similar resistance profiles yet, when combined, exhibit synergistic inhibition of wild type replicons and/or replicons carrying mutations conferring resistance to the HCV NS5A-targeting inhibitor. In addition, combinations of these molecules result in a higher genetic barrier to resistance, demonstrating their potential utility as novel combination therapies for treatment of HCV.
    Type: Application
    Filed: July 13, 2011
    Publication date: June 20, 2013
    Inventors: Jin-Hua Sun, Min Gao, Donald R. O'Boyle, II, Julie A. Lemm, Susan B. Roberts, Makonen Belema, Nicholas A. Meanwell
  • Hepatitis C virus assays
    Patent number: 7195885
    Abstract: The present invention includes an assay useful for identifying inhibitors of Hepatitis C virus (HCV) activity. Particularly, the present invention is directed to a dual HCV assay useful for high throughput screening that quantifies both the amount of HCV RNA replication inhibitory activity associated with a test compound and the amount of cytotoxicity associated with that test compound. The present invention also includes compounds discovered using this assay, compositions containing such compounds and methods of treating Hepatitis C by the administration of such compounds. The present invention also includes reporter assays using enzymes associated with HCV RNA replication, as well as a cell line having ATTC Accession No. PTA-4583.
    Type: Grant
    Filed: August 12, 2003
    Date of Patent: March 27, 2007
    Assignee: Bristol-Myers Squibb Company
    Inventors: Min Gao, Julie A. Lemm, Donald R. O'Boyle, Peter Nower, Karen Rigat, Jin-hua Sun
  • Hepatitis C virus assays
    Publication number: 20040121975
    Abstract: The present invention includes an assay useful for identifying inhibitors of Hepatitis C virus (HCV) activity. Particularly, the present invention is directed to a dual HCV assay useful for high throughput screening that quantifies both the amount of HCV RNA replication inhibitory activity associated with a test compound and the amount of cytotoxicity associated with that test compound. The present invention also includes compounds discovered using this assay, compositions containing such compounds and methods of treating Hepatitis C by the administration of such compounds. The present invention also includes reporter assays using enzymes associated with HCV RNA replication, as well as a cell line having ATTC Accession No. PTA-4583.
    Type: Application
    Filed: August 12, 2003
    Publication date: June 24, 2004
    Inventors: Min Gao, Julie A. Lemm, Donald R. O'Boyle, Peter Nower, Karen Rigat, Jin-Hua Sun